Medical Oncologist
Medicines
How do zoledronic acid and denosumab work, and who are they for?
Zoledronic acid and denosumab both slow the cells that break bone down, but in different ways. Zoledronic acid binds to bone and stops these cells, while denosumab blocks the signal they need. This page explains the biology simply, why cancer and hormone treatment weaken bone, and who benefits from each medicine.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
On this page
- How do zoledronic acid and denosumab work, and who are they for?
- The biology in four steps
- Situations where they are used
- The vocabulary, in plain language
- The limits of how they work
- Why zoledronic acid may lower recurrence after menopause
- Protecting bones from hormone treatment
- How the choice between them is made
- What people assume about how they work
- Common questions about how these medicines work
The short answer
How do zoledronic acid and denosumab work, and who are they for?
Bone is living tissue that is constantly renewed. Cells called osteoclasts break down small areas of old bone, and cells called osteoblasts build new bone to replace it. In healthy adults these two processes stay balanced. When breast cancer spreads to bone, cancer cells release signals that switch on osteoclasts, so bone is broken down faster than it is rebuilt. As bone breaks down, it releases growth factors that can feed the cancer cells, creating a cycle that weakens the skeleton and can cause pain, fractures and high blood calcium. Lowering oestrogen with aromatase inhibitors or early menopause also speeds up bone loss, in a different way. Zoledronic acid and denosumab both slow osteoclasts, but by different routes. Zoledronic acid is a bisphosphonate. It sticks firmly to the mineral surface of bone. When osteoclasts start breaking down that bone, they take up the medicine, which stops them working and causes them to die. Because it stays bound to bone, its effect lasts a long time. Denosumab is a laboratory-made antibody. It locks on to a signal called RANKL, which osteoclasts need to form, work and survive. Blocking RANKL quickly reduces bone breakdown, but the effect wears off within months once injections stop. These medicines are used for people with bone metastases, for bone protection during hormone treatment, and, for zoledronic acid, in postmenopausal women with early breast cancer.
They slow bone breakdown
Both target osteoclasts, the cells that remove bone.
Different routes
Zoledronic acid is taken up from bone. Denosumab blocks a signal.
Different lasting effects
Zoledronic acid lingers in bone. Denosumab wears off after stopping.
This page gives general information only. Your oncologist will explain whether you need one of them.How they work
The biology in four steps
A simple picture of what goes wrong in bone and how the medicines help.
Normal renewal
Osteoclasts remove old bone and osteoblasts rebuild it, keeping the skeleton strong.
Cancer in bone
Cancer cells switch on osteoclasts. Bone breaks down and releases factors that help cancer grow.
This is often called a vicious cycle.How zoledronic acid helps
It binds to bone. Osteoclasts absorb it as they work, which stops them and shortens their life.
How denosumab helps
It blocks RANKL, the signal osteoclasts need.
The result for both
- Less bone breakdown
- Stronger bones over time
- Fewer and later bone problems
Who they are for
Situations where they are used
Situation
Which medicine is usually considered
Breast cancer that has spread to bone
Either zoledronic acid or denosumab, given regularly
Bone thinning on aromatase inhibitors
Zoledronic acid or the lower-dose, six-monthly form of denosumab
Early breast cancer after menopause
Zoledronic acid, to slightly lower the chance of cancer returning in bone
High blood calcium from cancer
Zoledronic acid, with fluids through a drip
Significant kidney problems
Denosumab is often preferred, with close calcium checks
Words you will hear
The vocabulary, in plain language
- Osteoclast
- A cell that breaks down bone.
- Osteoblast
- A cell that builds new bone.
- Bone remodelling
- The constant process of removing and rebuilding bone.
- Monoclonal antibody
- A laboratory-made protein that locks on to one specific target, as denosumab does.
- Bone mineral density
- A measure of bone strength, checked with a DEXA scan.
- Hypercalcaemia
- High calcium in the blood, which can happen when cancer breaks down bone.
Being straight with you
The limits of how they work
Understanding the biology helps set realistic expectations.
They act on bone, not tumour cells
They weaken the cycle between cancer and bone, but they are not a cancer treatment on their own.
They cannot rebuild badly damaged bone quickly
A bone already weakened by cancer may still need radiotherapy, surgery or support.
The anti-cancer effect is limited to certain settings
A small reduction in bone recurrence has been shown only in postmenopausal early breast cancer with bisphosphonates.
What this page cannot tell you
It cannot tell you whether your bones need treatment. A scan, blood tests and your oncologist's review decide that.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Early breast cancer
Why zoledronic acid may lower recurrence after menopause
A large analysis combining many trials found that bisphosphonates given to postmenopausal women after early breast cancer slightly reduced cancer returning in bone and improved breast cancer survival.
The bone soil idea
Stray cancer cells can hide in bone. Bisphosphonates may make bone a less welcoming place for them to grow.
Why menopause matters
The benefit appeared in women with low oestrogen, either after natural menopause or with ovarian suppression.
Why not denosumab
A large trial of denosumab in early breast cancer did not show a reduction in recurrence, so it is used only for bone protection in this setting.
Hormone treatment
Protecting bones from hormone treatment
Oestrogen helps keep bones strong. Treatments that lower it speed up bone loss.
Who is at risk
Women on aromatase inhibitors, those with early menopause from treatment, and those with low bone density at the start.
How risk is checked
A DEXA scan measures bone density, and your team considers other risk factors such as age, earlier fractures and steroid use.
How the medicines help
Zoledronic acid or six-monthly denosumab reduce bone loss and fracture risk, alongside calcium, vitamin D and weight-bearing exercise.
Choosing
How the choice between them is made
Both work well, so practical factors often decide.
Kidney function
Zoledronic acid needs adequate kidney function. Denosumab can be used when kidneys are weaker.
Convenience
Denosumab is a quick injection. Zoledronic acid is a short drip but may be given less often for some purposes.
Long-term plans
Denosumab needs a plan for stopping, while zoledronic acid's effect fades slowly.
Commonly believed
What people assume about how they work
They kill cancer cells in bone.
They slow bone-destroying cells. Other treatments target the cancer.
They build brand-new bone.
They mainly reduce breakdown, which lets bone strength improve slowly.
Both medicines work in exactly the same way.
They act through different routes and behave differently after stopping.
Only people with bone metastases need them.
They are also used to protect bones during hormone treatment.
Questions we are asked
Common questions about how these medicines work
How quickly do they start working?
They start slowing bone breakdown within days to weeks, which blood tests can show. Stronger bones and fewer fractures take months. If you have bone pain, other treatments usually help faster, and bone-directed medicines work alongside them in the background.
Why does zoledronic acid last so long?
It binds tightly to the mineral in bone and is released only slowly as bone is renewed. That is why it can be given every few months or less often for some purposes, and why its protective effect fades gradually after stopping.
Why does stopping denosumab matter?
Denosumab does not stay in bone. When its effect wears off, osteoclasts can become very active, causing rapid bone loss and a higher risk of spinal fractures. A follow-on bisphosphonate is often used. Always plan stopping with your team.
Will they stop cancer spreading to my bones?
In postmenopausal women with early breast cancer, zoledronic acid slightly lowers the chance of cancer returning in bone. It does not prevent spread for everyone, and it has not shown this benefit in premenopausal women with working ovaries. Denosumab has not shown it either.
Do they help bones in men with breast cancer?
Yes. Men with breast cancer in the bones can receive these medicines, and men whose hormone treatment affects bone may also benefit. The way the medicines work is the same, and the precautions, such as dental care, apply equally.
Can I take bisphosphonate tablets instead of a drip?
Some bisphosphonate tablets are used for bone protection and, in some countries, for early breast cancer. They must be taken in a specific way to protect the food pipe. For bone metastases, drips or injections are usually preferred. Ask your team about suitable options.
Why do I need calcium and vitamin D?
When bone breakdown slows, bones take up more calcium from the blood, which can lower calcium levels. Calcium and vitamin D supplements help prevent this and support bone building. Your team will check levels and advise on doses.
Do I need a DEXA scan?
A DEXA scan is used when the aim is to protect bones from thinning, for example on aromatase inhibitors. It is less useful for bone metastases, where the cancer itself affects scan results. Your team will advise whether and how often you need one.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- The Lancet — Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
- National Cancer Institute — Denosumab
- National Cancer Institute — Zoledronic acid
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.